Merck-Moderna mRNA cancer therapy cut melanoma recurrence risk 42% in phase 3
In the 1,137-patient INTerpath-001 trial, adding the individualized mRNA therapy intismeran to pembrolizumab after surgery cut the risk of recurrence or death by 42%; overall survival data are not yet mature.